Amsacrine is safe in patients with ventricular ectopy
- 1 July 1988
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 28 (3) , 197-198
- https://doi.org/10.1002/ajh.2830280315
Abstract
Amsacrine is an active antileukemic agent known to induce cardiac arrhythmias, although the incidence of these cardiac events is low. Rhythm abnormalities associated with amsacrine use include the development of fatal tachyarrhythmias, but this risk can be minimized by ensuring a normal serum potassium level prior to drug administration. Even though amsacrine has been given safely to patients with pre-existing supraventricular arrhythmias, its safety in patients with ventricular ectopy has not been addressed. We describe two patients who underwent treatment with amsacrine without developing life-threatening dysrhythmias and show that ventricular ectopy does not contraindicate therapy with this agent.Keywords
This publication has 7 references indexed in Scilit:
- Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemiaCancer Chemotherapy and Pharmacology, 1987
- Amsacrine-associated cardiotoxicity: an analysis of 82 cases.Journal of Clinical Oncology, 1986
- Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemiaCancer, 1983
- PHASE-I AND PHASE-II TRIAL OF 4'-(9-ACRIDINYLAMINO)METHANESULFON-META-ANISIDIDE IN PATIENTS WITH ACUTE-LEUKEMIA1980